These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pimecrolimus--a safe and effective local immunomodulator in the treatment of inflammatory skin diseases. Lipozencić J Acta Dermatovenerol Croat; 2005; 13(1):63-9. PubMed ID: 15788149 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Van Leent EJ; Gräber M; Thurston M; Wagenaar A; Spuls PI; Bos JD Arch Dermatol; 1998 Jul; 134(7):805-9. PubMed ID: 9681343 [TBL] [Abstract][Full Text] [Related]
6. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Grassberger M; Baumruker T; Enz A; Hiestand P; Hultsch T; Kalthoff F; Schuler W; Schulz M; Werner FJ; Winiski A; Wolff B; Zenke G Br J Dermatol; 1999 Aug; 141(2):264-73. PubMed ID: 10468798 [TBL] [Abstract][Full Text] [Related]
7. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Meingassner JG; Grassberger M; Fahrngruber H; Moore HD; Schuurman H; Stütz A Br J Dermatol; 1997 Oct; 137(4):568-76. PubMed ID: 9390333 [TBL] [Abstract][Full Text] [Related]
8. Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases. Mollison KW; Fey TA; Gauvin DM; Sheets MP; Smith ML; Pong M; Krause R; Miller L; Or YS; Kawai M; Wagner R; Wiedeman PE; Clark RF; Gunawardana IW; Rhoades TA; Henry CL; Tu NP; BaMaung NY; Kopecka H; Liu L; Xie Q; Lane BC; Trevillyan JM; Marsh K; Luly JR Curr Pharm Des; 1998 Oct; 4(5):367-79. PubMed ID: 10197049 [TBL] [Abstract][Full Text] [Related]
9. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus. Stuetz A; Baumann K; Grassberger M; Wolff K; Meingassner JG Int Arch Allergy Immunol; 2006; 141(3):199-212. PubMed ID: 16926539 [TBL] [Abstract][Full Text] [Related]
10. A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseases. Mollison KW; Fey TA; Gauvin DM; Kolano RM; Sheets MP; Smith ML; Pong M; Nikolaidis NM; Lane BC; Trevillyan JM; Cannon J; Marsh K; Carter GW; Or YS; Chen YW; Hsieh GC; Luly JR J Invest Dermatol; 1999 May; 112(5):729-38. PubMed ID: 10233764 [TBL] [Abstract][Full Text] [Related]
11. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. Neckermann G; Bavandi A; Meingassner JG Br J Dermatol; 2000 Apr; 142(4):669-79. PubMed ID: 10792216 [TBL] [Abstract][Full Text] [Related]
12. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Queille-Roussel C; Paul C; Duteil L; Lefebvre MC; Rapatz G; Zagula M; Ortonne JP Br J Dermatol; 2001 Mar; 144(3):507-13. PubMed ID: 11260007 [TBL] [Abstract][Full Text] [Related]
13. [Development and pre-clinical aspects of pimecrolimus]. Stütz A; Grassberger M; Meingassner JG Hautarzt; 2003 May; 54(5):405-12. PubMed ID: 12719859 [TBL] [Abstract][Full Text] [Related]
15. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Wellington K; Jarvis B Drugs; 2002; 62(5):817-40. PubMed ID: 11929333 [TBL] [Abstract][Full Text] [Related]
16. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. Bornhövd E; Burgdorf WH; Wollenberg A J Am Acad Dermatol; 2001 Nov; 45(5):736-43. PubMed ID: 11606925 [TBL] [Abstract][Full Text] [Related]
18. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Mrowietz U; Graeber M; Bräutigam M; Thurston M; Wagenaar A; Weidinger G; Christophers E Br J Dermatol; 1998 Dec; 139(6):992-6. PubMed ID: 9990361 [TBL] [Abstract][Full Text] [Related]
19. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Simpson D; Noble S Drugs; 2005; 65(6):827-58. PubMed ID: 15819596 [TBL] [Abstract][Full Text] [Related]